Breaking News


Imiquimod cream for the treatment of actinic keratoses: Results of two placebo-controlled studies using two 3-week cycles


Two identical randomized, multicenter, placebo-controlled studies were conducted to evaluate the efficacy and safety of imiquimod cream 2.5% (n = 164), imiquimod 3.75% (n = 167) or placebo (n = 164) in actinic keratoses (AK) of the face and balding scalp. Imiquimod or placebo cream (up to 250 mg x 2) were applied once daily for two 3-week treatment cycles, with a 3-week no-treatment interval between cycles. Efficacy was assessed at 8 weeks post-treatment. The primary efficacy endpoint was the complete clearance rate, defined as the percentage of patients with zero lesion count at the end of the study. Complete clearance rates were 5.5, 25 and 34 in the placebo, imiquimod ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list